Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT03431948
Phase
PHASE1
Status
Completed

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    Nivolumab 240 mg given by intravenous infusion every 2 weeks
  • Cabiralizumab — DRUG
    Cabiralizumab 4 mg/kg given by intravenous infusion every 2 weeks
  • Urelumab — DRUG
    Urelumab 8 mg given by intravenous infusion every 4 weeks
  • Stereotactic Body Radiation Therapy — RADIATION
    Radiation to metastatic lesion(s) given at assigned dose levels based on lesion location and dose level being tested at time of enrollment. Doses range from 30 - 50 Gy.

Study Details

Study to determine the best dose of stereotactic body radiation therapy (SBRT) to be administered in combination with immunotherapy drugs including urelumab, cabiralizumab and nivolumab .

Key Dates

Start date
Mar 15, 2018
Status verified
Feb 2023
Primary completion
Feb 29, 2020
Completion
Apr 11, 2022

Study Design

Enrollment
60 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: SBRT with Nivolumab and Urelumab
    Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and urelumab.
  • Experimental: SBRT with Nivolumab and Cabiralizumab
    Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and cabiralizumab .

Primary Outcome Measure

Recommended dose of SBRT given in combination with immunotherapy [ Time Frame: 3 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Chicago Medical CenterChicagoIllinois60637-

Find similar trials in Chicago, IL

By research site
University of Chicago Medical Center· Chicago, IL

Related Studies